Incyte Corporation (NASDAQ:INCY) shares went down rapidly after the company declared that its melanoma drug trial has failed. The company conducted the Phase 3 trial to establish the effectiveness of its drug epacadostat in combination with KEYTRUDA from Merck & Co., Inc.’s (NYSE:MRK) for treating patients suffering from metastatic or...
Cancer immunotherapy has a promising future despite suffering a major setback last Friday. Incyte Corporation (NASDAQ:INCY) announced that its trial drug epacadostat had failed to help melanoma patients, and the company is calling off the trial altogether. Epacadostatwas meant to work together with Keytruda, Merck & Co., Inc. (NYSE:MRK)'s blockbuster...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) have for many years focused on the development of the rare-disease drug. But Thursday turned out to be a low moment for the two. That was after Pfizer Inc (NYSE:PFE), a component of Dow Jones unleashed strong late-stage results for the...
Novavax Inc (NASDAQ:NVAX) reported the promotion of Mr. John J. Trizzino to SVP, Chief Financial Officer (CFO) and Chief Business Officer (CBO). Trizzino has been working as SVP, Commercial Operations, since 2014. As Chief Business Officer, he is now accountable for all commercial and pre-commercial launch execution and strategy...
Proteostasis Therapeutics Inc (NASDAQ:PTI) went up 22% in premarket trade on Thursday after the therapeutic company reported a less-than-expected loss for the fourth-quarter. The company further announced that the Food and Drug Administration had granted its cystic fibrosis drug orphan drug designation. The Orphan drug designation grants the company seven...
Biopharmx Corp (NYSEAMERICAN:BPMX) will showcase to the medical community preliminary report from the cure of rosacea utilizing its novel topical gel named BPX-04. BPX-04 marks as the firm's latest addition to its clinical product pipeline. The details Biopharmx reported that BPX-04 marks as the second product advanced on the patent-pending company’s...
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has priced an underwritten public offering of 10 million shares of its common stock, fixed at $5.25 a share, before underwriting discounts. This offering is anticipated to close around January 22, 2018, depending on customary closing conditions. The buzz Arrowhead reported that the company has given the...
